View the full release here: "We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," ...

The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy ... and Sisunatovir for respiratory syncytical virus. Receive News & Ratings for ...

Death is a daunting prospect for many, but after a lot of reflection and work on herself, Bella Salsberry feels at peace with the life she's been granted.

Analyst Roanna Ruiz of Leerink Partners maintained a Buy rating on Cytokinetics (CYTK – Research Report), reducing the price target to ...

Aficamten, targeted at obstructive hypertrophic cardiomyopathy (oHCM), has completed NDA submissions ... which focuses on the discovery and development of muscle activators as potential treatment for ...

Dr. Eugene Braunwald is often called the father of modern cardiology. He calls that an exaggeration. "Maybe I've been around ...

Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies ... for non-obstructive hypertrophic cardiomyopathy (nHCM ...

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM ... on mavacamten and other drugs, reportedly because the biotech was ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 20 ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

Background: Symptoms are among the most important factors impacting quality of life (QOL) in hypertrophic cardiomyopathy (HCM) patients, and reflect a poor prognosis. Whether emotional stress can ...